• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·UK·Consumer Cyclical·ALRPD.PA
Share

Rapid Nutrition PLC Stocks

€ 2.57Last Updated 05.10.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

€ 1.32M

€ 2.57
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Rapid Nutrition PLC is a natural healthcare enterprise that researches, develops, and manufactures a diverse portfolio of science-backed health and wellness products. Its market presence extends across the United Kingdom, Australia, Asia, the United States, and other international regions. The company offers a range of organic and natural, scientifically formulated health food supplements, primarily distributed under the SystemLS and Leisa's Secret trademarks. Furthermore, it produces oral antiviral therapeutic solutions, marketed as Azurene, aimed at combating influenza and the common cold. The company was established in 2001 and is headquartered in London, UK.

Company Valuation

Greatly undervalued
7/7

Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. Specifically, the stock is undervalued on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

09.10.2026 16:48

The crisis in France could affect other countries. Which bonds are investors watching?

09.10.2026 16:34

Exxon Has Blocked a Settlement Agreement on the Kashagan Environmental Fine – Media Reports

09.10.2026 15:28

Morning in New York: A New Stress Test for the AI Rally

09.10.2026 15:17

With AI, it's possible to develop a drug twice as fast. Which companies is Cathie Wood betting on?

09.10.2026 15:00

TRex Bio IPO: Shares of Eli Lilly's Partner Pharmaceutical Company Are Now Available

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026